NanoFuse Biologics adds orthobiologics executive: 3 insights


NanoFUSE Biologics appointed Archie Yamada as vice president of product business development.

Here are three things to know:

1. Mr. Yamada has more than 19 years of experience in the medical device industry, specifically in orthobiologics, orthopedic trauma and joints as well as neurosurgical and craniomaxillofacial implants.

2. NanoFUSE Biologics is a KICVentures-acquired portfolio company distributed by SpineFrontier.

3. The proprietary NanoFUSE Bioactive Matrix is the only FDA-cleared demineralized bone matrix and synthetic bioactive glass technology combination. The NanoFUSE DBM putty has been used in upwards of 1,000 cases by more than 200 orthopedic surgeons in various applications.

More articles on biologics:

Connect Healthcare Collaboration selects Regenexx as solution to lower employers' orthopedic surgery costs

Zimmer Biomet to terminate exclusive distribution agreement with BoneSupport: 5 things to know

Medtronic's Kyphon HV-R Bone Cement receives 2nd indication: 4 key points

Copyright © 2023 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Podcast

Featured Whitepapers